Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH), the naturally occurring hypothalamic hormone that regulates the reproductive endocrine system. GnRH controls the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary gland. These hormones then regulate ovarian function, testicular function, ovulation, spermatogenesis, estrogen production, and testosterone production.
Gonadorelin is a 10-amino-acid peptide and is structurally identical or very similar to endogenous GnRH, depending on the salt form used. It has historically been used in humans for diagnostic evaluation of the hypothalamic-pituitary-gonadal axis and for pulsatile therapy in selected patients with hypothalamic GnRH deficiency. It is also FDA-approved in certain veterinary products for use in cattle.
Gonadorelin binds to GnRH receptors on gonadotroph cells in the anterior pituitary gland.
Activation of these receptors causes release of:
The downstream effects depend heavily on the pattern of exposure:
In men, increased LH may stimulate Leydig cells in the testes to produce testosterone. Increased FSH may support Sertoli cell function and spermatogenesis. In women, LH and FSH regulate follicular development, estrogen production, ovulation, and corpus luteum function.
Because gonadorelin acts upstream of the gonads, it may support endogenous reproductive hormone production when the hypothalamic-pituitary-gonadal axis is intact.
Potential benefits of gonadorelin depend on the clinical context and route/pattern of administration.
Potential benefits may include:
Gonadorelin is not a general testosterone replacement therapy and is not appropriate for all forms of hypogonadism. It requires an intact and responsive pituitary-gonadal axis to be effective.
Potential side effects may include:
Potential risks may include:
Patients using gonadorelin for fertility or hormone-related conditions should be medically monitored with appropriate laboratory testing.
Gonadorelin should generally be avoided or used only with specialist supervision in patients with:
Patients with infertility, hypogonadism, pituitary disease, or complex endocrine disorders should be evaluated by a qualified healthcare provider before using gonadorelin.
Gonadorelin has a complex regulatory history. A human gonadorelin acetate product, Lutrepulse, previously received FDA orphan drug approval in 1989. Gonadorelin products such as Factrel were also historically used for diagnostic testing of hypothalamic-pituitary function, but human commercial availability has changed over time.
Currently, gonadorelin is not commonly available as an active FDA-approved commercial human drug product in the United States.
Important distinctions:
Veterinary products such as Factrel® are FDA-approved for use in cattle only and are not human medications.
Human Studies
Gonadorelin and GnRH therapy have been studied extensively in humans for endocrine diagnosis and reproductive medicine.
Human studies have evaluated gonadorelin for:
Pulsatile GnRH therapy has been shown to induce gonadotropin secretion and restore fertility in selected patients with hypothalamic GnRH deficiency. Long-term pulsatile therapy can be physiologic because it mimics natural GnRH secretion rather than bypassing the hypothalamic-pituitary-gonadal axis.
## Animal & Veterinary Studies
Gonadorelin has also been extensively studied in animals, particularly cattle.
Veterinary studies have evaluated gonadorelin for:
FDA-approved veterinary gonadorelin products are used in cattle, but this does not imply approval or safety for human use.
Human Studies
## Animal & Veterinary Studies
The information provided on this page is intended for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease and should not be considered medical advice.
This content was generated with the assistance of artificial intelligence (AI) and should be reviewed by a qualified medical professional before publication or clinical use. AI-generated medical content may contain errors, omissions, or outdated information.
Gonadorelin has historical human clinical uses and FDA regulatory history, but current commercial availability and approval status may vary by product and indication. Veterinary gonadorelin products are not intended for human use. Individual results vary, and no specific outcome or benefit can be guaranteed. Patients should consult a qualified healthcare provider before beginning or changing any medical treatment.
R2 Medical Clinic uses medications sourced from compounding pharmacies. Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). Unlike FDA-approved medications, compounded drugs have not undergone FDA review for safety, effectiveness, or efficacy through the FDA drug approval process. While 503B outsourcing facilities are registered with and inspected by the FDA and must comply with Current Good Manufacturing Practice (CGMP) requirements, the compounded medications they produce are not individually approved by the FDA. Similarly, compounded medications prepared by 503A pharmacies are not FDA-approved and are primarily regulated by state boards of pharmacy, with FDA oversight under applicable federal law.
# Oxytocin